Biological Laboratory, INC.

Biological Laboratory, INC. was paid $24.85M by Medicaid between Jan 2018 and Dec 2024, across 217 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 33% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in California

Rank by total paid#40 of 561

Median peer was paid$222K

This provider vs. median112×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	179,160	$3.20M
2019	171,220	$2.07M
2020	109,931	$1.95M
2021	198,415	$4.49M
2022	260,999	$6.50M
2023	211,142	$3.41M
2024incomplete	316,194	$3.24M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	33%	143,258	84,875	$8.25M
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	10%	91,445	85,756	$2.53M
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	10.0%	89,678	84,134	$2.47M
87806		4.9%	49,802	37,558	$1.22M
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	4.7%	64,351	34,710	$1.17M
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	3.5%	45,936	40,553	$858K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	3.4%	23,575	14,176	$846K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	2.7%	25,855	9,279	$683K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	2.3%	58,422	30,506	$583K
80055		1.5%	11,996	11,967	$380K
83021		1.5%	43,522	42,735	$363K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	1.3%	82,322	76,880	$329K

205 more codes

84443	Thyroid stimulating hormone (TSH)	1.3%	44,871	$320K
80053	Comprehensive metabolic panel	1.2%	61,435	$293K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	1.2%	24,444	$292K
80061	Lipid panel	1.1%	46,835	$269K
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	1.1%	4,424	$266K
86780		1.1%	24,001	$261K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	1.0%	836	$260K
86481		<1%	4,712	$247K
86592		<1%	64,634	$222K
86003		<1%	878	$154K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	3,542	$136K
84702		<1%	10,426	$117K
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	<1%	1,427	$114K
87086	Culture, bacterial; quantitative colony count, urine	<1%	20,138	$88K
88142		<1%	6,401	$82K
87340		<1%	10,402	$76K
86762		<1%	6,283	$73K
87624	Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types	<1%	3,179	$66K
84439		<1%	16,429	$65K
86803		<1%	6,272	$57K
84153		<1%	6,895	$57K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	2,261	$56K
88305	Level IV - Surgical pathology, gross and microscopic examination	<1%	1,945	$56K
82607		<1%	9,724	$44K
82746		<1%	6,979	$43K
86235		<1%	345	$43K
81003		<1%	33,903	$36K
83880		<1%	2,823	$36K
80074		<1%	1,330	$34K
84403		<1%	2,099	$33K
86706		<1%	4,405	$32K
87081		<1%	6,286	$31K
0202U	Oncology (prostate), multianalyte, gene expression profiling	<1%	102	$30K
87522	Neg quan hep c or qual rna	<1%	1,018	$29K
S3600	Stat laboratory request (situations other than s3601)	<1%	11,831	$29K
82728		<1%	4,500	$28K
82274		<1%	4,146	$28K
U0002	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc	<1%	560	$28K
82951		<1%	2,797	$28K
87077		<1%	6,182	$27K
80164		<1%	3,355	$27K
82570		<1%	13,525	$25K
99000		<1%	7,615	$25K
87486		<1%	690	$25K
82043		<1%	10,397	$25K
84466		<1%	4,207	$25K
84480		<1%	3,261	$24K
86038		<1%	3,696	$22K
86790		<1%	2,510	$21K
84550		<1%	11,301	$21K
86704		<1%	2,742	$20K
82785		<1%	1,421	$19K
87481		<1%	542	$19K
80048	Basic metabolic panel (calcium, ionized)	<1%	4,795	$18K
87581		<1%	690	$18K
83735		<1%	4,845	$17K
86696		<1%	1,151	$16K
83540		<1%	5,433	$16K
87070		<1%	3,358	$16K
86709		<1%	2,332	$15K
82950		<1%	4,224	$15K
84436		<1%	5,605	$15K
81220	CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants	<1%	47	$15K
83655		<1%	1,409	$14K
87631		<1%	280	$14K
86705		<1%	1,886	$14K
84481		<1%	1,982	$13K
80159		<1%	931	$13K
86140		<1%	4,463	$13K
87801	Infectious agent detection by nucleic acid; amplified probe, multiple organisms	<1%	371	$12K
84100		<1%	6,573	$12K
86141		<1%	1,476	$12K
85730		<1%	3,342	$11K
86695		<1%	1,168	$11K
G2024	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source	<1%	493	$11K
86403		<1%	1,269	$11K
86430		<1%	4,351	$11K
87186		<1%	2,885	$11K
82947		<1%	4,371	$10K
85610		<1%	4,664	$10K
82248		<1%	4,473	$10K
85651		<1%	7,084	$9K
83970		<1%	695	$9K
84270		<1%	643	$9K
82378		<1%	2,017	$9K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	<1%	117	$9K
86376		<1%	772	$8K
84146		<1%	775	$8K
86635		<1%	370	$8K
82977		<1%	2,480	$8K
84479		<1%	2,775	$8K
85027		<1%	2,583	$7K
83001		<1%	658	$7K
36415	Collection of venous blood by venipuncture	<1%	14,249	$7K
84154		<1%	749	$6K
81015		<1%	8,597	$6K
82670		<1%	353	$6K
87210		<1%	2,353	$6K
87184		<1%	2,004	$6K
86225		<1%	448	$6K
P9604	Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge	<1%	4,885	$5K
82105		<1%	298	$5K
86901		<1%	2,349	$5K
82140		<1%	726	$5K
80178		<1%	1,204	$5K
86900		<1%	2,281	$5K
84134		<1%	588	$4K
83002		<1%	412	$4K
S5102	Adult day care, billed per day	<1%	49	$4K
P9603	Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled	<1%	980	$4K
83090		<1%	181	$4K
80076		<1%	1,227	$4K
86787		<1%	376	$4K
85045		<1%	1,189	$4K
83615		<1%	1,899	$3K
88312		<1%	490	$3K
86301		<1%	723	$3K
83690		<1%	1,196	$3K
84311		<1%	3,033	$3K
86735		<1%	280	$3K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	<1%	374	$3K
86765		<1%	280	$3K
82150		<1%	917	$3K
86769		<1%	99	$3K
83525		<1%	267	$3K
88313		<1%	463	$3K
82465		<1%	1,013	$3K
80177		<1%	416	$3K
86480		<1%	58	$3K
80051		<1%	437	$2K
80202		<1%	261	$2K
86677		<1%	282	$2K
86160		<1%	69	$2K
87804	Infectious agent antigen detection by immunoassay; Influenza, each type	<1%	275	$2K
83036	Hemoglobin; glycosylated (A1C)	<1%	3,546	$2K
83605		<1%	353	$2K
85007		<1%	1,340	$2K
82550		<1%	1,030	$2K
85018		<1%	1,461	$2K
87147		<1%	589	$2K
84156		<1%	460	$2K
83986		<1%	3,099	$2K
83516		<1%	57	$2K
84144		<1%	108	$2K
87150		<1%	74	$2K
87338		<1%	60	$1K
87529		<1%	28	$1K
86593		<1%	401	$1K
87536		<1%	44	$1K
86708		<1%	156	$1K
86039		<1%	203	$1K
86063		<1%	495	$1K
86304		<1%	309	$1K
81025		<1%	391	$1K
K1034	Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count	<1%	1,216	$1K
84703		<1%	218	$1K
85013		<1%	820	$1K
84681		<1%	50	$800.03
87177		<1%	74	$737.95
83718		<1%	144	$649.48
82533		<1%	108	$590.13
84478		<1%	228	$572.72
86694		<1%	55	$530.33
87807		<1%	72	$529.05
86300		<1%	91	$502.85
86850		<1%	203	$485.97
87634		<1%	17	$477.36
99058		<1%	43	$477.23
86200		<1%	122	$351.49
84484		<1%	70	$289.47
82565		<1%	197	$287.04
82310		<1%	193	$284.90
84402		<1%	12	$246.95
87517		<1%	16	$222.77
80185		<1%	44	$205.18
84460		<1%	74	$171.49
82040		<1%	97	$157.83
84520		<1%	167	$157.57
84075		<1%	119	$152.45
80069		<1%	52	$132.53
84132		<1%	59	$131.04
86800		<1%	15	$122.43
86060		<1%	28	$120.87
80156		<1%	14	$112.58
85048		<1%	135	$107.31
84295		<1%	45	$99.66
82747		<1%	12	$87.21
85049		<1%	340	$82.01
85014		<1%	130	$68.26
84450		<1%	61	$64.89
83721		<1%	49	$57.30
87045		<1%	13	$53.05
86356		<1%	12	$47.12
82435		<1%	24	$38.92
87088		<1%	12	$29.06
82247		<1%	25	$19.18
84155		<1%	26	$18.05
88311		<1%	15	$7.82
82652		0%	58	$0.00
83013		0%	53	$0.00
U0001	Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel	0%	15	$0.00
3046F		0%	44	$0.00
3045F		0%	12	$0.00
G2025	Payment for a telehealth distant site service furnished by a rural health clinic (rhc) or federally qualified health center (fqhc) only	0%	226	$0.00
3044F		0%	1,642	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialDAVID, EUFEMIA (CEO)